🔓 Unlock the full profile of Mark Alasandro (Allergan), including verified contact details, financial insights, and professional associations.
See Mark Alasandro Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: mar*****@all******.com
Mobile: 60877*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Mark Alasandro is the Founder and Principal Consultant at MZA Pharmaceutical Consulting, established in November 2019.
- Prior to founding MZA Pharmaceutical Consulting, Mark held leadership positions at major pharmaceutical companies, including Director roles at Nalpropion Pharmaceuticals (formerly Orexigen Therapeutics), Allergan, Merck, and Bristol-Myers Squibb (formerly DuPont Pharmaceuticals).
- At Nalpropion Pharmaceuticals, the tenure included overseeing critical projects until January 2019, contributing to the company's objectives in the competitive pharmaceutical landscape.
- During the time at Allergan, a publicly traded company under ABBV with a market capitalization of $112.4B, Mark was involved in strategic initiatives that enhanced product development and market positioning.
- The experience at Merck and Bristol-Myers Squibb further solidified Mark's expertise in leading teams and managing projects that directly impact drug development and regulatory processes.
- Mark's extensive employment history demonstrates a strong background in the pharmaceutical industry, showcasing a track record of successful project management and strategic decision-making.
- Throughout the professional journey, challenges were faced in navigating the regulatory landscapes and competitive market strategies within the pharmaceutical sector.
- Mark’s contributions to the industry reflect a commitment to advancing pharmaceutical consulting and improving health outcomes through effective leadership and innovative approaches.